Savita Kanade, MSc

CRS:

BJMC

Role:

Community and Outreach Team

Position:

Community Coordinator

Email:

Savita_kanade@hotmail.com

Savita Kanade is working as Community and Outreach Coordinator for NIH funded clinical trials at BJGMC-CRS, Pune, India. At present she is serving as Field Representative on A5300B/I2003B/PHOENIx study.

As part of NIH funded HIV/AIDS and Tuberculosis clinical trials, since 2007, she was involved in recruitment and retention of participants in clinical trials and in identifying issues related to understanding barriers to participation and retention, addressing stigma and discrimination, administering informed consent, managing socio-cultural issues during the study participation, addressing opportunistic infections such as TB, etc.

She is also involved in networking and communication with state level agencies like National TB Elimination Programme (NTEP), Maharashtra State AIDS Control Society (MSACS)  and various NGOs working for  HIV/AIDS and Tuberculosis. 
She is acting as site liaison to the Community Advisory Board (CAB) and facilitates local CAB representation at GCAB and CSS at ACTG network and ICAB at IMPAACT network. 

She is been involved in translating the study related material (informed consent forms, education material, CRFs, study flyers, etc.) into local language.

As an Anthropologist, she was involved in public health research for 15 years. She was active in research related to reproductive health, family planning, gender based domestic violence, formation of sexual partnerships, pathways in resolving unintended pregnancy among youth, and parent child communication on sex related issues.

  • Field Representative for ACTG 5300/IMPAACT 2003 MDR TB Feasiblity Study PHOENIx and ACTG 5300B/IMPAACT 2003B MDR TB Household Study PHOENIX
  • Chorghade GP; Barker M; Kanade S; Fall CH,” Why are rural Indian women so thin? Findings from a village in Maharashtra”, Public Health Nutrition. Feb;9(1):9-18,2006. (PMID :16480528)
  • DrMallika Alexander, Dr Laila Garda, Ms Savita Kanade, ShireenJejeebhoy, BelaGanatra, “Romance and Sex: Pre-Marital Partnership Formation among Young Women and Men, Pune District , India” Reproductive Health Matters, 2006 Nov;14(28):144-55. (PMID:17101433)
  • Alexander M, Garda L, Kanade S, Jejeebhoy S, Ganatra B. “Correlates of premarital relationships  among unmarried youth in Pune district, Maharashtra, India.” International Family Planning Perspective, 2007 Dec;33(4):150-9 (PMID: 18178539)
  • Debalina De, AartiKinikar, P. S. Adhav, SunandaKamble, PrasannaSahoo,HariKoli, Savita Kanade, VidyaMave,, Nishi Suryavanshi,NikhilGupte, Amita Gupta, and JyotiMathad, “Source Case Investigation for Children with TB Disease in Pune, India”, Tuberculosis Research and Treatment, vol 2014 (PMID: 25243086 PMCID:PMC4163291)
  • Mathad JS, Bhosale R, Sangar V, Mave V, Gupte N, Kanade S, Nangude A, Chopade K, Suryavanshi N, Deshpande P, Kulkarni V, Glesby MJ, Fitzgerald D, Bharadwaj R, Sambarey P, Gupta A,  “Pregnancy differentially impacts performance of latent tuberculosis diagnostics in a high-burden setting”, PLoS One. 2014 (PMID:24658103, PMCID:PMC3962385)

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More